TITLE:
Genetic and Demographic Outcomes in a Population of Patients with Headache and Facial Pain
AUTHORS:
Jonathan Eskenazi, Miriam Nuno, Steven Graff-Radford, Oana M. Dumitrascu
KEYWORDS:
Headache, Pharmacogenetics, Cytochrome P450, Cerebrovascular Risk, Cardiovascular Risk
JOURNAL NAME:
Journal of Behavioral and Brain Science,
Vol.8 No.6,
June
6,
2018
ABSTRACT: Background: Pharmacogenetics information about cytochrome p450 (CYP450) polymorphism in
patients with headaches is limitedly reported. Similarly, the genetic factors
linking various headache types and vascular disorders are poorly described. We
aimed to characterize the genetic profile of a cohort of headache and facial
pain subjects. Methods: Medical records of consecutive headache subjects
that underwent PersonaGeneTM testing were reviewed. PersonaGeneTM panel assessed CYP450,
apolipoprotein E (ApoE), methylene tetrahydrofolate reductase (MTHFR), Factor
II, Factor V Leiden and Vitamin K epoxide reductase complex subunit 1 (VKORC1).
Demographic information, headache diagnosis and genetic profiling were analyzed
and compared with data obtained from the general population. Results: Out of 130 headache patients, 91.3% were Caucasian and 70.8% had migraine.
Compared to the general Caucasian population, our Caucasian headache patients
were significantly different for CYP3A4/A5 and CYP2D6 (p Conclusion: Distinctive profiles for CYP450, ApoE, Factor V Leiden and VQORC1 were observed
in our Caucasian headache cohort. These results may impact headache subjects’
pharmacological treatment options and vascular risk ascertainment.